TegoScience Inc
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.
TegoScience Inc - Asset Resilience Ratio
TegoScience Inc (191420) has an Asset Resilience Ratio of 44.78% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how TegoScience Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down TegoScience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩36.80 Billion | 44.78% |
| Total Liquid Assets | ₩36.80 Billion | 44.78% |
Asset Resilience Insights
- Very High Liquidity: TegoScience Inc maintains exceptional liquid asset reserves at 44.78% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
TegoScience Inc Industry Peers by Asset Resilience Ratio
Compare TegoScience Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AGP Ltd
KAR:AGP |
Pharmaceuticals | 0.71% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620 |
Pharmaceuticals | 4.28% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Sam-A Pharm. Co. Ltd
KQ:009300 |
Pharmaceuticals | 34.37% |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040 |
Pharmaceuticals | 5.22% |
|
WooGene B&G Co. Ltd
KQ:018620 |
Pharmaceuticals | 3.35% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
Annual Asset Resilience Ratio for TegoScience Inc (2015–2024)
The table below shows the annual Asset Resilience Ratio data for TegoScience Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.06% | ₩27.34 Billion | ₩52.52 Billion | +9.30pp |
| 2023-12-31 | 42.76% | ₩20.91 Billion | ₩48.91 Billion | -0.67pp |
| 2022-12-31 | 43.43% | ₩22.31 Billion | ₩51.36 Billion | +1.65pp |
| 2021-12-31 | 41.78% | ₩21.31 Billion | ₩51.00 Billion | -3.79pp |
| 2020-12-31 | 45.58% | ₩22.97 Billion | ₩50.40 Billion | -0.32pp |
| 2019-12-31 | 45.90% | ₩22.29 Billion | ₩48.57 Billion | +22.22pp |
| 2018-12-31 | 23.67% | ₩11.26 Billion | ₩47.56 Billion | +1.76pp |
| 2017-12-31 | 21.92% | ₩10.43 Billion | ₩47.59 Billion | -23.31pp |
| 2016-12-31 | 45.22% | ₩20.19 Billion | ₩44.64 Billion | +33.58pp |
| 2015-12-31 | 11.65% | ₩3.00 Billion | ₩25.76 Billion | -- |